The anti-human CD20 CAR mRNA encodes a chimeric antigen receptor (CAR) that specifically targets the CD20 antigen expressed on B cells. The CD20 CAR mRNA is primarily suited for treating relapsed or refractory B-cell malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. When delivered via mRNA, this approach provides a non-integrating, controllable, and rapid method for generating CAR-expressing immune cells — minimizing genomic risk while enabling flexible dosing and manufacturing.